Clinical trials · New York
Leukemia clinical trials in New York
We’re tracking 178 recruiting leukemia studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT05702645Recruiting
Down syndrome long-term study after leukemia treatment
This study follows children and young adults with Down syndrome who have survived acute leukemia (ALL or AML) to learn about their longer-term health after treatment ends. It may help families and doctors understand what health problems to watch for and how to provide better follow-up care.
Albany, New YorkAges 6–39 - NCT05475925RecruitingPhase 1/Phase 2
Test drug DR-01 for specific blood cancer types
This early-phase study tests DR-01 to treat large granular lymphocytic leukemia (LGLL) or certain aggressive T-cell or cytotoxic lymphomas. It aims to see whether the drug is safe and can shrink or control the cancer.
New York, New YorkAges 18 years+ - NCT05304377RecruitingPhase 1
Early trial drug for chronic-phase CML after prior treatments
This Phase 1 study tests ELVN-001 in people with chronic-phase chronic myeloid leukemia (CML) who have had limited benefit or side effects from other CML medicines. It may help shrink leukemia activity safely and find the best dosing for people who still need treatment options.
New York, New YorkAges 18 years+ - NCT04988555RecruitingPhase 1/Phase 2
Study of an investigational drug for high-risk acute leukemia
This Phase 1/2 study tests enzomenib (DSP-5336) in people with relapsed or hard-to-treat acute leukemia (and, in some places, certain other blood cancers). The goal is to see how the drug works and how safe it is, especially for leukemia cases with specific genetic changes (KMT2A/MLL or NPM1).
New York, New YorkAges 12 years+ - NCT04872478RecruitingPhase 1
Early-phase drug safety and dosing study for relapsed blood cancers
This Phase 1 trial tests MRX-2843 in teenagers and adults whose leukemia has come back or did not respond to prior treatment. The main goals are to find safe dosing and learn how the body processes the drug.
New York, New YorkAges 12 years+ - NCT04269902RecruitingPhase 3
Early treatment check for high-risk CLL/SLL
This Phase 3 trial studies an early treatment approach for people with high-risk CLL or SLL who have not yet needed standard therapy. It aims to see if treating earlier can improve outcomes while keeping side effects manageable.
Auburn, New YorkAges 18 years+ - NCT03802695RecruitingPhase 1
Orca-Q pill to help during stem cell transplant
This Phase 1 trial studies Orca-Q to see if it is safe and works when added around the time of an allogeneic (donor) stem cell transplant for certain blood cancers. If you qualify, the study may offer a new option for managing the transplant immune response.
New York, New YorkAges 12–78 - NCT03666000RecruitingPhase 1
Azer-cel for B-cell lymphoma and leukemia that has returned
This trial tests an investigational cell therapy called Azer-cel for people with certain types of blood cancer (non-Hodgkin lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, or B-cell acute lymphoblastic leukemia) that has come back or not responded to previous treatments. The therapy uses your own immune cells that have been modified to find and attack cancer cells.
New York, New YorkAges 18 years+ - NCT05947851RecruitingPhase 3
Nemtabrutinib plus venetoclax versus standard add-on therapy
This Phase 3 study tests whether adding nemtabrutinib to venetoclax works better than the usual next treatment approach (venetoclax plus rituximab) in people with relapsed or treatment-resistant CLL/SLL. It may help by improving how well the cancer responds after at least one prior therapy.
Albany, New YorkAges 18 years+ - NCT07354074RecruitingPhase 2
Study of asciminib for children with Ph+ CML
This trial tests an oral medication called asciminib in children and teens with a type of leukemia called Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It aims to see if the drug is safe and effective for patients who are newly diagnosed or whose current treatment has stopped working or caused side effects.
New York, New YorkAges 1–18 - NCT04243785RecruitingPhase 1
Testing BTX-A51 for hard-to-treat AML or high-risk MDS
This Phase 1 study tests BTX-A51 in adults with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It’s designed to see if the treatment can be given safely and to learn how it works in people whose standard treatments have not helped or are no longer an option.
New York, New YorkAges 18 years+ - NCT07638007Recruiting
How targeted therapy affects thinking and memory in blood cancer
This study examines whether a new type of cancer medication affects thinking, memory, and focus in people with chronic myeloid leukemia (CML) or chronic lymphocytic leukemia (CLL). Researchers will compare people starting this medication with healthy volunteers to understand any changes.
Rochester, New YorkAges 18 years+ - NCT07605416RecruitingPhase 2
Testing New Drug Combination for Plasma Cell Leukemia
This study tests a new combination of medicines to treat plasma cell leukemia, a rare blood cancer. The trial aims to help patients newly diagnosed with this condition by using drugs that work against cancer cells in different ways.
Buffalo, New YorkAges 18–80 - NCT07586618RecruitingPhase 1
New Drug 4A10 for Hard-to-Treat Lymphoblastic Leukemia or Lymphoma
This is an early-stage study testing a new experimental drug (4A10) in patients whose acute lymphoblastic leukemia or lymphoblastic lymphoma has returned or stopped responding to standard treatments. Researchers want to learn if the drug is safe and how it works in the body.
New York, New YorkAges 18 years+ - NCT07581002RecruitingPhase 2/Phase 3
New AML Treatment With Three Drug Combination Study
This study tests a new three-drug combination (pivekimab sunirine, venetoclax, and azacitidine) for newly diagnosed acute myeloid leukemia in patients who cannot tolerate intensive chemotherapy. The goal is to see if this combination is safe and effective at controlling the disease.
The Bronx, New YorkAges 18 years+ - NCT07437950RecruitingPhase 2
Comparing treatment lengths for venetoclax in older adults with newly diagnosed acute myeloid leukemia
This study tests whether a shorter or longer course of the drug venetoclax works better for older adults with a type of blood cancer called acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. The goal is to find the best treatment duration to control the cancer while reducing side effects.
Buffalo, New YorkAges 60 years+ - NCT07400029RecruitingPhase 2
Obecabtagene autoleucel for B-cell ALL in remission
This trial tests a new cell therapy called obecabtagene autoleucel (a 'living drug' made from your own immune cells) for people with a type of blood cancer (B-cell ALL) that has responded to initial treatment but may still have tiny traces. The goal is to see if it can prevent relapse after remission.
Commack, New YorkAges 40 years+ - NCT07392242RecruitingPhase 2
Ivosidenib, azacitidine, and venetoclax for acute myeloid leukemia
This trial tests a combination of three targeted drugs for people with a specific type of AML that has an IDH1 mutation. The goal is to see if the combination helps control the leukemia and if continuing with just ivosidenib can keep it in remission.
Commack, New YorkAges 60 years+ - NCT07321652RecruitingPhase 3
Sonrotoclax plus zanubrutinib for untreated CLL or SLL
This trial tests whether adding a new drug, sonrotoclax, to the standard treatment zanubrutinib works better for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. It's for patients aged 65 and older who need therapy due to symptoms or blood cell issues.
Glens Falls, New YorkAges 65 years+ - NCT07306832RecruitingPhase 1
Study of IV Pivekimab Sunirine for Children with Relapsed AML
This study tests an experimental IV drug called pivekimab sunirine for children whose acute myeloid leukemia (AML) has returned or not responded to previous treatments. The drug targets a specific marker on leukemia cells (CD123) to try to kill them.
Valhalla, New YorkAges 6 months–17 years - NCT07283094RecruitingPhase 1
FHD-286 with decitabine and venetoclax for AML
This early-phase trial tests a new study drug called FHD-286 combined with two standard AML medicines (decitabine and venetoclax). It is for people with a high-risk type of AML that is either newly diagnosed (and you cannot have strong chemotherapy) or has come back after one prior treatment.
The Bronx, New YorkAges 18 years+ - NCT07277231RecruitingPhase 3
Comparing two drug combinations for untreated CLL
This trial tests a new combination of drugs (sonrotoclax plus zanubrutinib) against another standard combination (venetoclax plus acalabrutinib) for people with chronic lymphocytic leukemia (CLL) who have not had treatment before. The goal is to see which combination works better.
New York, New YorkAges 18 years+ - NCT07223021RecruitingPhase 3
Fludarabine dosing study for B-cell ALL
This study tests a different dose of the chemotherapy drug fludarabine before CAR T-cell therapy (tisagenlecleucel) for children and young adults with B-cell acute lymphoblastic leukemia. The goal is to see if the new dose works better at helping the body accept the CAR T cells while keeping side effects manageable.
New York, New YorkAges 1 year+ - NCT07218510RecruitingPhase 2
Venetoclax, obinutuzumab, then epcoritamab for untreated CLL/SLL
This trial tests a new combination of three drugs for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had treatment yet. The goal is to see if this approach helps control the disease with fewer side effects.
New York, New YorkAges 18 years+
Leukemia trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting leukemia studies listed above.
- Memorial Sloan Kettering Cancer Center · 10 studies
- Columbia University Irving Medical Center · 4 studies
- Memorial Sloan Kettering Westchester · 4 studies
- Montefiore Medical Center · 4 studies
- Roswell Park Comprehensive Cancer Center · 4 studies
- Memorial Sloan Kettering Nassau · 3 studies
- Glens Falls Hospital · 2 studies
- Icahn School of Medicine at Mount Sinai / Mount Sinai Hospital · 2 studies
What taking part in a leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Leukemia trials in other states
Common questions
- Are there leukemia clinical trials in New York?
- Yes. We're currently tracking 178 recruiting leukemia studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a leukemia study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New leukemia studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.